Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure
PLOS One · 03.08.2026 · 21 (8) · e0355201
DOI: 10.1371/journal.pone.0355201 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 03.08.2026. Verfasst von Phongthana Pasookhush und 6 weiteren Autor:innen. Beteiligte Einrichtung: Siriraj Population Health and Nutrition Research Group, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thail…. Hauptthemen laut MEDLINE: Pharmacogenetics, Electronic Health Records. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine Siriraj Hospital, Mahidol University..
Abstract (Originalsprache)
Pharmacogenomic (PGx) data in Thailand remain limited, and genetics-only surveys rarely quantify “realized actionability”—the overlap between actionable PGx phenotypes and real-world medication exposure. We profiled 4,662 Thai adults using SNP-array data and a pre-specified PGx panel (11 genes; 26 markers) with a hybrid required/optional calling policy for diplotype/phenotype assignment. CPIC level A/B gene–drug relationships were linked to hospital electronic medical record (EMR) prescription/dispensation data to quantify drug-specific realized actionability. Overall callability across gene-results was 98.62%, exceeding 99% for most genes and lower for CYP2C19 (95.99%) and NUDT15 (90.28%). Across nine phenotype-coded genes, 95.99% carried ≥1 CPIC-actionable result (median 2; IQR 2–3). Actionable prevalence among callable individuals was highest for CYP3A5 (58.54%) and CYP2C19 (56.67%), followed by ABCG2 (45.10%) and UGT1A1 (27.37%). EMR linkage identified 1,529 (32.58%) participants exposed to ≥1 study medication; omeprazole (n = 658) and statins were most common (atorvastatin n = 606; simvastatin n = 603). Among users, actionable phenotypes were frequent for CYP2C19 –omeprazole (55.02%) and SLCO1B1 –statins (21.95–23.05%). In conclusion, an Asian-optimized SNP array supports scalable PGx phenotyping in Thai adults. EMR linkage quantifies realized actionability and highlights high-yield targets ( CYP2C19 –proton pump inhibitors; SLCO1B1 –statins) for pre-emptive implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Siriraj Population Health and Nutrition Research Group, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Siriraj Center of Research Excellence for Diabetes and Obesity (SiCORE-DO), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Phongthana Pasookhush, Korapat Mayurasakorn
Förderung
- Faculty of Medicine Siriraj Hospital, Mahidol University.
Zitieren
APA
Pasookhush, P., Suta, S., Pumeiam, S., Mongkolsucharitkul, P., Pinsawas, B., Ophakas, S., & Mayurasakorn, K. (2026). Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure. PLOS One, 21(8), e0355201. https://doi.org/10.1371/journal.pone.0355201
Vancouver
Pasookhush P, Suta S, Pumeiam S, Mongkolsucharitkul P, Pinsawas B, Ophakas S, et al. Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure. PLOS One. 2026;21(8):e0355201. doi:10.1371/journal.pone.0355201
BibTeX
@article{Pasookhush2026,
author = {Pasookhush, Phongthana and Suta, Sophida and Pumeiam, Sureeporn and Mongkolsucharitkul, Pichanun and Pinsawas, Bonggochpass and Ophakas, Suphawan and Mayurasakorn, Korapat},
title = {Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0355201},
doi = {10.1371/journal.pone.0355201}
}
EUVIMED